Aaron Levitt

Aaron Levitt

Aaron Levitt is an independent investment analyst and author living in State College, Pennsylvania. His work appears in several high profile publications in both print and on the web.

As an advocate for long-term globally oriented investing, Aaron believes that exchange traded funds have leveled playing field for Main Street. Following global macro-economic trends, investors now have several avenues to create great long term portfolios.

Aaron is a graduate of The Pennsylvania State University where he studied Economics and International Business. Aside for helping regular investors develop winning portfolios, his current projects include writing his first book on alternative energy investing.

Follow his picks and pans on Twitter at @AaronLevitt.

Recent Articles

There’s Still Plenty of Good Among the Bad With JD.com Stock

Despite a rocky short-term, the long-term is better at JD.com. That could make the dip in JD stock worth buying for the long haul.

Tesla Should Go Private, But Don’t Bank on It Happening

Investors may not want to bank on Tesla going private. There are just too many moving parts to get the deal done at TSLA.

Don’t Count Out These 5 Active Mutual Funds

While the performance may not justify their cost for many active mutual funds, there are still plenty worth owning. Here are five of the best.

Why Waymo Can Become a Huge Driver for Alphabet Stock

Alphabet's Waymo looks poised to be a game changer for the online grocery delivery sector and can boost GOOG stock.

Walmart’s Next Earnings Will Be All About Omnichannel

When Walmart reports earnings next week, it'll be all about omnichannel and "bricks and clicks." It's what investors need to focus on when it comes to WMT stock.

5 Companies Making Giant Buybacks

Buybacks are quickly becoming a hot topic on Wall Street, and with buyback activity surging, it's important to find the best companies that are doing them the right way.

5 Smart-Beta ETFs That Are Actually Making Intelligent Moves

These smart-beta ETFs have been performing well in 2018 despite any volatility. Here's why investors should consider adding them to their portfolios.

3 Bond ETFs That Are Doing Much Better Than Bill Gross

These three bond ETFs have a good shot at dethroning the Bond King, Bill Gross, as they have managed to outperform him lately. It might be time to make a switch.

Abiomed Has a Strong Long-Term Prognosis

Abiomed is still killing it longer term. Sales are growing and the outlook for ABMD stock remains strong. The opportunity to buy the heart pump-maker is here.

Despite Delivering on Earnings, Halliburton Stock Is Still Not a Buy

Halliburton had a great quarter, but it's still not a buy. A variety of big-time issues are affecting HAL stock.